OncoPharm

ASCO's updated 2017 antiemetic guidelines recommend NK-1 antagonists to prevent CINV with standard Q 3 week carboplatin (i.e. AUC 5-6), but how good are the data to support that? We dive into the supporting data.

Discover the ins and outs of carboplatin, its unique mechanism compared to cisplatin, and the intentional design to minimize kidney toxicity. Explore its versatile applications in treating various cancers and learn about the innovative AUC dosing strategy. Delve into the Calvert equation for calculating doses influenced by GFR, and understand the implications of creatinine variations. Plus, gain insights on managing toxicities, desensitization protocols, and why personalized dosing leads to better patient outcomes.

ADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.

Dive into the complex world of immunotherapy rechallenge, where experts weigh the risks and benefits for patients with prior immune-related adverse events. Discover case studies that illuminate the importance of shared decision-making and careful patient monitoring. Explore strategies for managing lower-grade toxicity and the challenges faced during cancer treatment. With valuable insights into timing and management protocols, this discussion is vital for anyone interested in cutting-edge cancer care.

Reviewing the recent Lancet publication of CASPIAN (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext) --> durvalumab + chemo in extensive stage small cell lung cancer.

Recapping updates from ESMO 2019. Topics include FLAURA (osimertinib), 5-year OS analyses of immunotherapy in metastatic NSCLC & melanoma, EGFR/BRAF/MEK inhibition in BRAF-V600E colorectal cancer, PARP inhibitors in ovarian cancer, and a possible cabazitaxel comeback.

The Landmarks in #Oncopharm series returns on the 10-year anniversary of this landmark paper (https://www.nejm.org/doi/10.1056/NEJMoa0904544) comparing daunorubicin 90 mg/m2 vs. 45 mg/m2 for AML induction.

Discussion of FDA's approval of lenvatinib & pembrolizumab for endometrial cancer followed by a comparison of TITAN v. ENZAMET prompted by apalutamide's latest approval.

Recapping the NY Times (https://www.nytimes.com/interactive/2018/10/26/magazine/netflix-diagnosis-series-joe.html) & Netflix collaboration "Diagnosis" about a possible Ibrutinib ADR. We also the discuss the value of case reports for the #OncoPharm community.

The 2nd installment of the OncoPharm Morbidity & Mortality series discussed a published case report (https://www.ncbi.nlm.nih.gov/pubmed/28782406). We discuss the approach to take when a patient experiences unexpectedly extreme toxicity and the role pharmacogenetics may play. Suggested resource: https://cpicpgx.org